Shareprice
13 Jul 2024

About

FluoGuide A/S is a clinical stage biotechnology company focused on developing drugs for maximizing surgical outcomes by making cancer fluorescent.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

Board of directors

Peter Mørch Eriksen - Chairman of the board FluoGuide

Peter Mørch Eriksen

Chairman of the board

Peter Mørch Eriksen has more than 20 years of experience in the medtech/life science sectors, both in Denmark and internationally. With a career marked by significant roles, he has recently returned to the position of CEO at BioPorto A/S, a role he previously held until 2021. Before reassuming the role as CEO at BioPorto, Peter was actively involved as a board member of the company. His extensive background includes serving as the CEO of Sense A/S and holding key positions such as Vice President of Medtronic in the USA and Denmark. These roles have endowed Peter with a wealth of knowledge in driving growth, executing restructuring, and securing funding in technologically advanced and complex organizations. Peter’s professional foundation is in accounting, complemented by various management courses. He maintains a diverse portfolio of board memberships and advisory roles: he chairs the board of Monsenso A/S, is a board member at BioPorto A/S, chairman in AptaShape Aps and Director of PMEconsult ApS. Additionally, he contributes his expertise to the Medical Device and Diagnostics Advisory Committee of Cincinnati Children’s Hospital Medical Center in Ohio, US.

Born in 1960. Chairman of the board since 2021

Independent in relation to both the Company and executive management as well as larger shareholders.

Number of  FluoGuide shares 115,669 and 87,500 warrants (Partly owned via PME Holding ApS)

Mats Thorèn - Vice chairman of the board FluoGuide

Mats Thorèn

Vice chairman of the board

Mats Thorén has 25 years of experience from the financial markets, where he has worked in the Healthcare both as an equity analyst and in corporate finance. For the past seventeen years, Mats Thorén has been a Healthcare investment professional. He has worked with Nalka Life Science AB and MedCap AB and now manages his own company, Vixco Capital, with a focus on investments. He currently serves on the boards of Xbrane BioPharma AB (Stockholm Smallcap), Arcoma AB (Stockholm First North) and Herantis Pharma Oy (Stockholm and Helsinki First North). He has previous board experience from C-Rad AB (Stockholm First North), as well as Cellartis AB, Duocort AB, MIP Technologies AB and several other private companies. Mats Thorén has studied at the Stockholm School of Economics focusing on Accounting and Financial Economics as well as studies in medicine at the Karolinska Institute in Stockholm.

Born in 1971. Board member since 2021

Independent in relation to both the Company and executive management as well as larger shareholders.

Number of FluoGuide shares 1,216 and 0 warrants

Andreas Kjaer - Member of the board FluoGuide

Andreas Kjaer

Member of the board

Andreas Kjaer, is an MD, PhD, DMSc and professor at the University of Copenhagen and chief physician at Rigshospitalet, the National University Hospital of Denmark. His research is focused on molecular imaging with PET and PET/MRI in cancer and cardiovascular disease and his achievements include development of several new tracers that have reached first-in-humans clinical use. He is the holder of an ERC Advanced Grant, has published more than 400 peer-review articles and has received numerous prestigious scientific awards over the years. Andreas Kjaer also has an MBA from Copenhagen Business School.

Born in  1963. Board member since 2018.

Dependent in relation to both the Company and executive management as well as larger shareholders.

Number of FluoGuide shares  2,126,107 (owned via Life Science Aps) and privately 121,400 warrants .

 

Michael Engsig - Member of the board FluoGuide

Michael Engsig

Member of the board

Michael Thyrring Engsig has extensive experience within the pharmaceutical industry with more than 20 years of international experience in both capital markets and publicly listed companies. This includes a successful track record in general management, R&D and commercial functions. Since 2019 Michael has been CEO at Nykode Therapeutics, Norway.

Michael holds a M.Sc. in chemistry with a specialization in biotechnology from the Technical University of Denmark and a graduate diploma in Business Administration (HD) from Copenhagen Business School.

Born in 1972. Board member since 2023

Independent in relation to both the Company and executive management as well as larger shareholders.

Number of FluoGuide shares 0 and 7,500 warrants

Donna Haire - Member of the board FluoGuide

Donna Haire

Member of the board

Donna Haire is CEO of The Eriah Group, Inc. which specializes in global regulatory, quality, clinical and medical affairs consulting services for drugs, biologics, medical devices/in vitro diagnostics, and combination products. She is a seasoned executive with over 30 years of experience in healthcare, pharmaceutical, and medical device industries. She has extensive experience in regulatory, quality, clinical affairs, operations, business development, and R&D. Donna Haire has held positions as the Executive Vice President at On Target Laboratories, Vice President, Head of Medical Care Global Regulatory Affairs at Bayer, Senior Vice President of Regulatory, Quality, Clinical, and Medical Affairs at AngioDynamics and has held senior level positions at Philips Healthcare and Medtronic. She was an Adjunct Professor at the University of Akron School of Law. She served as an AdvaMed Technical and Regulatory Board Committee Member and a Board of Directors Authorized Representative. Donna Haire was designated a U.S. regulatory expert to lead multiple international trade negotiations in regulatory convergence. She has been a keynote speaker and panelist for numerous regulatory and compliance events worldwide.

Donna holds an M.S. in Biology from Cleveland State University and a B.S. in Biology from The University of Akron.

Board member since 2024

Independent in relation to both the Company and executive management as well as larger shareholders.

Number of FluoGuide shares 0 and 0 warrants

Roger Gunnarsson -  FluoGuide

Roger Gunnarsson

Roger is co-founder and senior advisor at Segulah Medical Acceleration, a Scandinavian growth equity investment firm. Prior to SMA, Roger worked as an international investment banker for 25 years, with a focus on healthcare for the last 18 years. Roger is recognised as a leading financial and M&A advisor in the international life science sector. Roger has a global network of contacts, across many of the world’s largest healthcare corporation and smaller start-ups as well, ensuring access to relevant decision makers at potential partners.

Roger holds a M.Sc. in Business Administration and Economics from Stockholm School of Economics.

Board member since 2024

Independent in relation to both the Company and executive management as well as larger shareholders.

Number of FluoGuide shares 0 and 0 warrants